Recipharm and CTC Forms New Collaboration
News Jun 18, 2014
CTC Clinical Trial Consultants AB and Recipharm Pharmaceutical Development AB have announced that they have entered into a collaboration.
Together the two companies will offer a complete set of packages for Phase I studies including development and manufacture of clinical trial material. The scope will cover planning, performing and evaluation of the clinical trial.
Maria Lundberg, General Manager Recipharm Pharmaceutical Development AB commented: “I am delighted about this collaboration. CTC has excellent experience in clinical trials and a unique phase I unit at Uppsala University Hospital (Akademiska Sjukhuset). Together we will be able to offer customers faster and more cost-efficient phase I studies. We can from now on take full responsibility for coordination of the work which might be valuable to small virtual companies.”
Bengt Dahlström, CEO of CTC Clinical Trial said “I am very pleased that CTC and Recipharm now can offer a joint service which will benefit from the companies longstanding expertise in contract development and manufacturing and early clinical research. This systematic integrated approach will help our clients to shorten project time-lines and at the same time obtain more information on the desirable properties of the drug formulation. Adaptive design is a key element in getting more information from each study and modifying the design based on the data obtained all within a single protocol.”
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE